Annovis Bio, Inc. (ANVS) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US03615A1088
Annovis Bio, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 0.00 USD |
| Operating income | -29.70 m USD |
| EBIT | -29.55 m USD |
| Net income | -28.85 m USD |
| Diluted EPS – continuing operations | -1.40 USD |
Full history since 2009, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Annovis Bio, Inc.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
More stocks
- CareView Communications Inc (CRVW)
- BioInvent International AB (BINV.ST)
- Brilliant Earth Group, Inc. (BRLT)
- DocGo Inc. (DCGO)
- DSwiss Inc (DQWS)
- Cytosorbents Corp (CTSO)
- CVRx, Inc. (CVRX)
- Creative Media & Community Trust Corp (CMCT)
- HG Holdings, Inc. (STLY)
- Picard Medical, Inc. (PMI)
- Quoin Pharmaceuticals, Ltd. (QNRX)
- Skillsoft Corp. (SKIL)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.